


MYPRAVAC[®] SUIS

A well thought out vaccinal strategy against *M. hyopneumoniae*



CONTROL ...

Mycoplasma hyopneumoniae

Is a **key factor** for **preventing**

Serious economic losses on farms



- Enzootic Pneumonia is a worldwide disease caused by the *Mycoplasma hyopneumoniae* pathogen.¹
- More than 90% of the swine farms in the world are affected by infections with *Mycoplasma hyopneumoniae*.²
- The pulmonary lesions induced by *Mycoplasma hyopneumoniae* have a negative influence on the growth of pigs and directly affect the yields of our farm.³
- For every 10% of lung surface affected by lesions, a pig's Average Daily Gain (ADG) decreases by 37.4 gr/day.³
- Enzootic Pneumonia aggravates respiratory diseases caused by co-infections by PRRSV and PCV2.^{4,5}



Photo 1: Lung of an unvaccinated pig with more than 40% of the surface area affected.




Photo 2: Lungs of a healthy animal vaccinated with MYPRAVAC SUIS.

MYPRAVAC[®] SUIS

Mypravac[®] suis enables you to establish the best strategy for your farm against *Mycoplasma hyopneumoniae*

Mypravac[®] Suis is a bi-dose vaccine, for piglets, used around the world that can be adapted to any vaccinal programme according to each farm's circumstances.

Mypravac[®] Suis is a vaccine that does NOT place any limits on developing the most intelligent vaccinal strategy and, therefore, efficacy against Enzootic pneumonia on your farm:



Mypravac[®] Suis can be applied from when piglets are one week old facilitating handling and guaranteeing efficacious and lasting protection until the end of fattening.



Mypravac[®] Suis is a vaccine that induces Safe and Efficacious Vaccinal Immunity (S.E.V.I), whether maternal antibodies are present or not, thanks to the application of a bi-dose.



Mypravac[®] Suis exclusive adjuvant induces S.E.V.I without enhancing Porcine Circovirus and reduces the risk of increasing the severity of respiratory disease caused by co-infection with the PRRS virus.^{4,7}




Mypravac[®] Suis is a vaccine that helps control the infection pressure on the farm.⁸

HIPRAMUNE[®]

The key to its success is in the design of its adjuvant:

It is the only vaccine on the market that combines levamisole + carbomer, two potent adjuvants. It is an adjuvant with a double effect: the combination of levamisole and carbomer offers higher and longer-lasting immunity due to the synergy of the properties of both compounds.



It improves the introduction of the vaccinal antigen to the immunological system.

Possesses high affinity for the B and T lymphocytes, which means it facilitates contact between the vaccinal antigen and the immune system (B and T lymphocytes, among others) and so it achieves a rapid response from the immune system.



Extraordinary DEPOT EFFECT: sequestration and delayed release of the vaccinal antigen.

The narrow bond between the carbomer and the vaccinal antigen protects it from attacks from macrophages and lymphocytes, thereby preventing its rapid elimination, which enables the colostral barrier to be overcome and induces a long-lasting stimulation of the immune system.

MYPRAVAC® SUIS



Its efficacy improves farm's profitability and ensures the producer's economic benefits



Table 1. Results of the productive parameters obtained according to the treatment group:

	Group Vaccinated with Mypravac® Suis	Control Group	Difference
Nº days of occupation per pig	121.2	125	-3.8
Mean weight gain in fattening period (kg)	84.37	76.82	7.55
Average Daily Gain (g/day)	696	614	82
Mean weight per carcass (kg)	76.50	69.06	7.44
Mean consumption of feed (kg)/pig during fattening period	200.2	205.7	-5.5
Conversion index	2.37	2.67	-0.3

Two treatment groups were studied in a field trial⁶ conducted to evaluate the efficacy and profitability of Mypravac® Suis. One group was vaccinated with 2 doses of Mypravac® Suis and the other group was left unvaccinate. The reproductive parameters were assessed up until the time the animals were taken to the abattoir.

Mypravac® Suis makes a farm profitable due to its efficacy and safety:

Reduces, by up to **four days**, the number of days the animals occupy the fattening unit.

It increases pig's productive yield and increases the ADG up to **82 g/day**.

Reduces infection pressure on the farm by decreasing the percentage of animals positive to M.hyo by means of PCR.⁸

Improves conversion indices up to **300g less per Kg of meat**.

The economic benefits obtained with Mypravac® Suis are the result of an intelligent and precise strategy for controlling enzootic pneumonia.

MYPRAVAC® SUIS

The most intelligent solution for a complex problem:

Inactivated vaccine against *Mycoplasma hyopneumoniae* in injectable suspension. **COMPOSITION PER DOSE (2 ML):** *Mycoplasma hyopneumoniae* inactivated strain J ≥ 1.0 DE₈₀ guinea pig; Methyl p-Hydroxybenzoate 2.4 mg. Adjuvant; Levamisole (chlorhydrate) 1.8 mg; Carbomer 10 mg. **INDICATIONS:** Swine: Prevention of enzootic pneumonia. Active immunization of healthy, susceptible piglets when between 7- and 10-days-old. Vaccination with MYPRAVAC® SUIS reduces pulmonary lesions and weight loss associated with infection by *Mycoplasma hyopneumoniae*. **ADMINISTRATION AND DOSAGE:** Swine: 2 ml/Piglet. Administration route: deep intramuscular injection. Recommended vaccinal plan: Initial vaccination when 7-10 days old. Revaccinate 21 days later. Shake before use. **WITHDRAWAL PERIOD:** Meat: 2 days. **SPECIAL STORAGE PRECAUTIONS:** Store and transport between +2 and +8 °C. Do not freeze. **PRESENTATION:** 50 dose vial. **UNDER VETERINARY PRESCRIPTION. FOR VETERINARY USE ONLY.**



Bibliography:

1. D. Maes et al. Control of Mycoplasma Myopneumoniae infection/ Veterinary Microbiology 126 (2008) 297–309.
2. Thacker EL. Mycoplasmal diseases. In Straw B, Zimmerman JJ, D'Allaire S and Taylor DJ, des. Diseases of Swine. 9th ed. Ames, Iowa State University Press; 2006.
3. B. Straw et al. Estimation of the cost of pneumonia in swine herds, JAVMA 81(989), Vol 195.
4. Eileen L. theacker et el, Journal of clinical microbiology (1999).
5. Opriessnig T et al Vet Pathology 41 (2004).
6. Llopart et al. The pig Journal (2002) 49:70-83.
7. Opriessnig et al. (2004) IPVS. Hamburg.
8. M. Sibila, M. Nofrañas, S. López-Soria, J. Segalés, O. Valero, A. Espinal, P. Riera, P. Llopart, M. Calsamiglia. " Mycoplasma hyopneumoniae infection dynamics in a farm in vaccinated and non-vaccinated pigs". Proceedings 19th IPVS (2006).

- Key Maximum flexibility at the time it is applied: from when piglets are one week old.
- Key Efficacious and reliable protection throughout the entire fattening period.
- Key Induction of safe and efficacious immunity (S.E.V.I).
- Key Excellent profitability: improving economic results of your production.



Laboratorios Hipra, S.A.
Avda. la Selva, 135
17170 Amer (Girona)
Spain

Tel. (34) 972 43 06 60
Fax. (34) 972 43 06 61
hipra@hipra.com
www.hipra.com